Mainz Biomed
MYNZ • NASDAQ
Mainz Biomed is a medical - diagnostics & research company in the healthcare sector trading on NASDAQ, led by CEO Guido Baechler, with a market cap of $9.0M.
CEOGuido Baechler
Next Earnings
Upcoming earnings announcement for Mainz Biomed
Date
Wednesday, April 15, 2026 (in 2 months)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
FY 2025
EPS Estimate
-$2.52
Revenue Estimate
$957.0K
Earnings History
Past 8 earnings reports for Mainz Biomed
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | FY 2024 | -$22.36Est: -$2.80 | -698.6% | $894.0KEst: $300.0K | +198.0% | — |
| Oct 21, 2024 | H1 2024 | -$19.60Est: -$8.80 | -122.7% | $520.8KEst: $300.0K | +73.6% | — |
| Apr 9, 2024 | Q4 2023 | -$9.60Est: -$12.80 | +25.0% | $214.8KEst: $270.0K | -20.5% | — |
| Nov 16, 2023 | Q3 2023 | -$15.60Est: -$18.80 | +17.0% | $181.7KEst: $330.0K | -44.9% | — |
| Aug 15, 2023 | Q2 2023 | -$22.40Est: -$16.80 | -33.3% | $248.9K | — | — |
| May 16, 2023 | Q1 2023 | -$18.00 | — | $250.1K | — | — |
| Apr 10, 2023 | FY 2022 | -$74.40Est: -$70.40 | -5.7% | $529.9KEst: $697.5K | -24.0% | — |
| Sep 7, 2022 | H1 2022 | -$36.40 | — | $239.8K | — | — |